Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related postsAFFIRM-AL Study Protocol AmendmentJune 23, 2022Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid CardiomyopathyResults From ATTRibute-CM and Its Open-Label ExtensionNovember 12, 20252023 Summer NewsletterJuly 13, 2023 Previous post2026 Winter NewsletterNext postCARES Phase III clinical program did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosis
